ZNTL— Zentalis Pharmaceuticals, Inc.

MaterialsPharmaceutical Preparations$302M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues from Licensing and Sales of Intellectual Property	$0-100.0%	$67.4M	—	—
Research and development	$107.3M-36.0%	$167.8M-11.5%	$189.6M+9.8%	$172.7M
Zentera in-process research and development	$0	$0-100.0%	$45.6M	$0
General and administrative	$37.7M-56.7%	$87.1M+35.4%	$64.4M+18.0%	$54.6M
Restructuring	$7.8M	$0	—	—
Goodwill impairment	$0-100.0%	$3.7M	—	—
Total operating expenses	$152.8M-40.9%	$258.6M-13.7%	$299.5M+31.8%	$227.3M
Loss from operations	-$152.8M+20.1%	-$191.2M+36.2%	-$299.5M-31.8%	-$227.3M
Investment and other income, net	$16.2M-36.5%	$25.5M+12.8%	$22.6M+277.8%	$6.0M
Net loss before income taxes	-$136.6M+17.5%	-$165.7M+40.2%	-$276.9M-25.1%	-$221.3M
Income tax expense (benefit)	$442K+149.7%	$177K+129.5%	-$601K-28.1%	-$469K
Loss on equity method investment	$0	$0-100.0%	$16.0M-1.6%	$16.3M
Net loss	-$137.1M+17.4%	-$165.9M+43.3%	-$292.3M-23.3%	-$237.1M
Net loss attributable to noncontrolling interests	$0+100.0%	-$28K+75.4%	-$114K+62.9%	-$307K
Net loss attributable to Zentalis	-$137.1M+17.4%	-$165.8M+43.2%	-$292.2M-23.4%	-$236.8M
Net loss per common share outstanding, basic (in dollars per share)	-$1.91+18.0%	-$2.33+47.9%	-$4.47+0.2%	-$4.48
Net loss per common share outstanding, diluted (in dollars per share)	-$1.91+18.0%	-$2.33+47.9%	-$4.47+0.2%	-$4.48
Common shares used in computing net loss per share, basic (in shares)	$71869.00+1.1%	$71080.00+8.7%	$65409.00+23.7%	$52857.00
Common shares used in computing net loss per share, diluted (in shares)	$71869.00+1.1%	$71080.00+8.7%	$65409.00+23.7%	$52857.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.